Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Gains from Investment Securities (2016 - 2025)

OptimizeRx's Gains from Investment Securities history spans 10 years, with the latest figure at $5000.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 98.8% year-over-year to $5000.0; the TTM value through Jun 2025 reached $448000.0, up 124.46%, while the annual FY2024 figure was $911000.0, 41.42% down from the prior year.
  • Gains from Investment Securities for Q2 2025 was $5000.0 at OptimizeRx, down from $87000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.5 million in Q1 2022 and bottomed at -$51.1 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $80000.0 (2023), against an average of -$2.7 million.
  • The largest YoY upside for Gains from Investment Securities was 4340.37% in 2022 against a maximum downside of 228001.14% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$51.1 million in 2021, then soared by 102.56% to $1.3 million in 2022, then plummeted by 286.35% to -$2.4 million in 2023, then surged by 113.3% to $324000.0 in 2024, then crashed by 98.46% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Gains from Investment Securities are $5000.0 (Q2 2025), $87000.0 (Q1 2025), and $324000.0 (Q4 2024).